Cite
HARVARD Citation
Piccini, J. et al. (2022). Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet. 399 (10333), pp. 1383-1390. [Online].